EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain

Martine B Grenon, Erika N Cline, Jasna Jerecic, Elizabeth Johnson, Eric Siemers, Cynthia A Lemere

Alzheimer's & Dementia · 2026-06 · 22 (6)

DOI: 10.1002/alz.71509 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 01.06.2026. Verfasst von Martine B Grenon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Building for Transformative Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Brain, Antibodies, Monoclonal, Amyloid beta-Peptides. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Acumen Pharmaceuticals (US), National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Immunotherapy targeting amyloid beta (Aβ) is limited by amyloid‐related imaging abnormalities (ARIA), hypothesized to result from the direct binding of anti‐Aβ monoclonal antibodies (mAbs) to vascular cerebral amyloid angiopathy (CAA), eliciting an immune response. METHODS Immunofluorescent staining was used to characterize ex vivo plaque and vascular binding of recombinant FDA‐approved lecanemab and clinical candidate sabirnetug (ACU193) in 30 min and 24 h fixed APP:hE4 mouse brain tissue. RESULTS Fixation time was a key factor influencing Aβ antigen labeling with prolonged fixation differentially affecting pan‐Aβ and mAb immunoreactivity. Compared with ACU193, lecanemab showed greater cortical plaque and cerebellar vascular labeling and encompassed a larger fraction of total pan‐Aβ and β‐pleated‐sheet‐rich signal, reflecting both mAb target abundance and selectivity. DISCUSSION These findings emphasize that experimental protocols and antibody properties jointly shape the observed mAb binding patterns and highlight differences that may contribute to antibody‐specific ARIA risk observed clinically.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrainAntibodies, MonoclonalAmyloid beta-PeptidesAnimalsMiceMice, TransgenicPlaque, AmyloidAmyloid beta-Protein Precursor

Stichwörter der Autor:innen

amyloid‐related‐imaging abnormalitiesanti‐Aβ monoclonal antibodycerebral amyloid angiopathyimmunofluorescent staining

Substanzen

Antibodies, MonoclonalAmyloid beta-PeptidesAmyloid beta-Protein Precursor

Autor:innen und Institutionen

  • Building for Transformative Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
  • Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Acumen Pharmaceuticals, Newton, Massachusetts, USA.

Förderung

  • NINDS NIH HHS
  • Acumen Pharmaceuticals (US)
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Grenon, M. B., Cline, E. N., Jerecic, J., Johnson, E., Siemers, E., & Lemere, C. A. (2026). Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain. Alzheimer's & Dementia, 22(6). https://doi.org/10.1002/alz.71509

Vancouver

Grenon MB, Cline EN, Jerecic J, Johnson E, Siemers E, Lemere CA. Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain. Alzheimer's & Dementia. 2026;22(6). doi:10.1002/alz.71509

BibTeX
@article{Grenon2026,
  author = {Grenon, Martine B and Cline, Erika N and Jerecic, Jasna and Johnson, Elizabeth and Siemers, Eric and Lemere, Cynthia A},
  title = {Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {6},
  doi = {10.1002/alz.71509}
}
Kostenlos starten →